Gossamer Bio, Inc. SEC filings GOSS
Gossamer Bio, Inc. has 484 filings in SEC EDGAR's recent list, going back to Jan 19, 2018. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Apr 24, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Apr 24, 2026 | Apr 24, 2026 |
| 10-K | Annual report | Mar 17, 2026 | Dec 31, 2025 |
| ARS | Annual report to shareholders | Apr 29, 2025 | Apr 28, 2025 |
| 10-K | Annual report | Mar 13, 2025 | Dec 31, 2024 |
| ARS | Annual report to shareholders | Apr 26, 2024 | Apr 26, 2024 |
| 10-K | Annual report | Mar 5, 2024 | Dec 31, 2023 |
| ARS | Annual report to shareholders | Apr 28, 2023 | Apr 28, 2023 |
| 10-K | Annual report | Mar 17, 2023 | Dec 31, 2022 |
| 10-K | Annual report | Mar 3, 2022 | Dec 31, 2021 |
| 10-K | Annual report | Feb 26, 2021 | Dec 31, 2020 |
| 10-K | Annual report | Mar 24, 2020 | Dec 31, 2019 |
| 10-K | Annual report | Mar 22, 2019 | Dec 31, 2018 |
Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GOSS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1728117
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.